FOLD Relative Valuation
FOLD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, FOLD is overvalued; if below, it's undervalued.
Historical Valuation
Amicus Therapeutics Inc (FOLD) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 3.55. The fair price of Amicus Therapeutics Inc (FOLD) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：9.95
Fair
41.70
PE
1Y
3Y
5Y
Trailing
Forward
26.35
EV/EBITDA
Amicus Therapeutics Inc. (FOLD) has a current EV/EBITDA of 26.35. The 5-year average EV/EBITDA is 40.32. The thresholds are as follows: Strongly Undervalued below -251.73, Undervalued between -251.73 and -105.71, Fairly Valued between 186.34 and -105.71, Overvalued between 186.34 and 332.37, and Strongly Overvalued above 332.37. The current Forward EV/EBITDA of 26.35 falls within the Historic Trend Line -Fairly Valued range.
24.21
EV/EBIT
Amicus Therapeutics Inc. (FOLD) has a current EV/EBIT of 24.21. The 5-year average EV/EBIT is -122.40. The thresholds are as follows: Strongly Undervalued below -1358.09, Undervalued between -1358.09 and -740.25, Fairly Valued between 495.44 and -740.25, Overvalued between 495.44 and 1113.28, and Strongly Overvalued above 1113.28. The current Forward EV/EBIT of 24.21 falls within the Historic Trend Line -Fairly Valued range.
4.20
PS
Amicus Therapeutics Inc. (FOLD) has a current PS of 4.20. The 5-year average PS is 7.13. The thresholds are as follows: Strongly Undervalued below 1.22, Undervalued between 1.22 and 4.17, Fairly Valued between 10.08 and 4.17, Overvalued between 10.08 and 13.03, and Strongly Overvalued above 13.03. The current Forward PS of 4.20 falls within the Historic Trend Line -Fairly Valued range.
5.91
P/OCF
Amicus Therapeutics Inc. (FOLD) has a current P/OCF of 5.91. The 5-year average P/OCF is 1641.65. The thresholds are as follows: Strongly Undervalued below -11767.28, Undervalued between -11767.28 and -5062.82, Fairly Valued between 8346.11 and -5062.82, Overvalued between 8346.11 and 15050.58, and Strongly Overvalued above 15050.58. The current Forward P/OCF of 5.91 falls within the Historic Trend Line -Fairly Valued range.
12.84
P/FCF
Amicus Therapeutics Inc. (FOLD) has a current P/FCF of 12.84. The 5-year average P/FCF is -32.11. The thresholds are as follows: Strongly Undervalued below -276.30, Undervalued between -276.30 and -154.21, Fairly Valued between 89.99 and -154.21, Overvalued between 89.99 and 212.09, and Strongly Overvalued above 212.09. The current Forward P/FCF of 12.84 falls within the Historic Trend Line -Fairly Valued range.
Amicus Therapeutics Inc (FOLD) has a current Price-to-Book (P/B) ratio of 13.32. Compared to its 3-year average P/B ratio of 21.76 , the current P/B ratio is approximately -38.79% higher. Relative to its 5-year average P/B ratio of 18.25, the current P/B ratio is about -26.99% higher. Amicus Therapeutics Inc (FOLD) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -2.47%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -4.22% , the current FCF yield is about -100.00% lower.
13.32
P/B
Median3y
21.76
Median5y
18.25
0.32
FCF Yield
Median3y
-2.47
Median5y
-4.22
Competitors Valuation Multiple
The average P/S ratio for FOLD's competitors is , providing a benchmark for relative valuation. Amicus Therapeutics Inc Corp (FOLD) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 19.46%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of FOLD increased by 5.63% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -54.19 to -217.70.
The secondary factor is the Revenue Growth, contributed 19.46%to the performance.
Overall, the performance of FOLD in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Amicus Therapeutics Inc (FOLD) currently overvalued or undervalued?
What is Amicus Therapeutics Inc (FOLD) fair value?
How does FOLD's valuation metrics compare to the industry average?
What is the current P/B ratio for Amicus Therapeutics Inc (FOLD) as of Dec 05 2025?
What is the current FCF Yield for Amicus Therapeutics Inc (FOLD) as of Dec 05 2025?
What is the current Forward P/E ratio for Amicus Therapeutics Inc (FOLD) as of Dec 05 2025?